CorestemChemon Partners with ATG Lifetech to Expand Organoid and Transcriptomics Capabilities

CorestemChemon, a GLP-certified preclinical CRO from South Korea, formed a strategic partnership with ATG Lifetech, a company specializing in transcriptome analytics and organoid-based modeling12.

The collaboration targets delivering next-generation, transcriptomics-powered, organoid-based preclinical testing for pharmaceutical and biotech companies globally, particularly across the U.S., Europe, and Asia2.

Together, they will co-develop disease-relevant organoid models (for liver, heart, and blood-brain barrier applications) and a transcriptome-based evaluation platform for predictive drug efficacy and safety profiling12.

Their platform aims to provide high-throughput transcriptomics analytics to improve tumorigenicity studies, differentiating true from false positives12.

The use of organoid-based assays, combined with whole-transcriptome analysis, is expected to enable up to 5x greater predictive accuracy in toxicity and efficacy screening over conventional 2D cell cultures, helping de-risk drug development pipelines and reduce timelines12.

The partnership also provides regulatory-aligned expertise for clients targeting FDA/EMA pathways12.

Sources:

1. https://trial.medpath.com/news/56e12d6d356eda38/corestemchemon-partners-with-atg-lifetech-to-advance-organoid-based-preclinical-testing

2. https://www.prnewswire.com/news-releases/corestemchemon-expands-global-cro-reach-with-atg-lifetech-targeting-next-gen-preclinical-services-302509269.html